Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)
An Open-label Study to Evaluate the Long-term Safety and Tolerability of AFQ056 in Adolescent Patients With Fragile X Syndrome
Sponsor: Novartis Pharmaceuticals
Terminated
The study treatment failed to demonstrate efficacy in target population in two other clinical studies (CAFQ056B2214 and CAFQ056A2212).
Other terminated trials from Novartis Pharmaceuticals
Other Fragile X Syndrome trials with similar outcome
Listed as NCT01433354, this PHASE2/PHASE3 trial focuses on Fragile X Syndrome and remains terminated or withdrawn. Sponsored by Novartis Pharmaceuticals, it has been updated 11 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2_PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2_PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2_PHASE3
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .